Press release
Rosacea Therapeutics Demand to Exceed US$ 2 Billion in 2019
Soolantra (topical ivermectin) received the FDA approval recently, for the use in the treatment of inflammatory lesions of rosacea.
The FDA’s approval for a topical cream RHOFADE (Oxymetazoline Hydrochloride) paved the way for the drug in the rosacea therapeutics, exclusively for persistent facial erythema in adults.
A tentative approval by the FDA has allowed the inclusion of Zenavod capsules (doxycycline) in rosacea therapeutics. These capsules are particularly used against pustules and papules, i.e. the specific inflammatory lesions associated with the condition in adults.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/18793
While these FDA approvals for rosacea therapeutics were registered in 2017, the decently growing rate of the introduction of new FDA-approved drugs is likely to provide a strong push to the revenue expansion of rosacea therapeutics landscape.
With an expanding rosacea patient pool, most prominently in Europe and North America, the revenue growth prospects for global rosacea therapeutics landscape appear to be on an impressive trajectory over the coming years. In a new intelligence report published by Persistence Market Research (PMR), the global sales of rosacea therapeutics are likely to receive major benefits from the development of newer formulations of rosacea therapeutics, especially alpha agonists.
A senior research analyst at PMR says, “The largest business opportunity is created by the increasing rosacea instances subsequently followed by inadequate definite curative therapeutics, insufficiently satisfactory as a first-line treatment. Rosacea therapeutics market players are targeting this opportunity leading to strategic new drug developments”.
Request for Report Methodology @: https://www.persistencemarketresearch.com/methodology/18793
In the consolidated competitive landscape of rosacea therapeutics market, four leading companies account for over 75% share of the total market value, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., Foamix Pharmaceuticals Ltd., and Bayer A.
PMR’s report on global rosacea therapeutics market provides deep-dive insights on the competitive landscape through thorough key company profiling and evaluation of their recent strategic developments.
“The available range of drugs in rosacea therapeutics necessarily play a palliative, short-term role in addressing the consequences of rosacea. However, the current treatment line still fails to provide a long-term therapy, let alone target the root cause of rosacea. The rosacea therapeutics space has been constantly witnessing R&D efforts with an objective to break through this ever-unmet need, which continues to be hampered by the lack of understanding of the disease itself,” explains the analyst, further adding, “There remains a huge gap between the existing rosacea therapeutics and market demand. The rate of treatment is also significantly low, prompting at the upcoming business opportunities for rosacea therapeutics market stakeholders”.
Off-label Pharmaceuticals Favor Sales Growth of Rosacea Therapeutics Landscape
Growing use of off-label drugs is providing a strong impetus to the revenue growth of rosacea therapeutics landscape, as some of them are highly popular for use in refractory cases, including botox, corticosteroids, and sulfacetamides. While the use of off-label drugs prevails for effectively treating rosacea, it is highly non-recommended and invalid according to the FDA and a few European Medicine Agencies. Persistent use off-label, non-recommended drugs continues to elevate the demand prospects for rosacea therapeutics.
Key Insights Drawn from Global Rosacea Therapeutics Market Report
At an estimated year on year revenue growth of just-under 6%, the global demand for rosacea therapeutics is projected to account for the revenue of over US$ 2 billion in 2019.
Around 75% share of the total market revenue is held by alpha agonists and antimicrobials that are the most sought after drug classes employed in rosacea therapeutics worldwide.
Retinoids and tropicals are projected for a promising rate of adoption in coming years.
Retail sales, owing to wider penetration as a sales channel, make up for around 3/4th of the global market value.
Although the report points to a higher year over year revenue growth for institutional sales of rosacea therapeutics, the escalating pace of healthcare privatization and expanding pharmaceutical retail sales remain the key driving forces for retail growth.
Get access to full summary @: https://www.persistencemarketresearch.com/market-research/rosacea-treatment-market.asp
Mature markets in Europe and North America hold a collective share of more than 95% in the total market revenue. However, Europe remains the top ranking region, as indicated by the report.
Key manufacturers are currently targeting these two regions for strengthening their distribution networks and thereby achieving higher RoI.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rosacea Therapeutics Demand to Exceed US$ 2 Billion in 2019 here
News-ID: 1464670 • Views: …
More Releases from Persistence Market Research
Europe Calf Milk Replacer Market to Reach US$1,657.2 Mn by 2032 | Driven by Risi …
The Europe calf milk replacer market is poised for significant growth over the coming years. The market size is projected to reach US$1,018.6 million in 2025 and is anticipated to expand to US$1,657.2 million by 2032, registering a robust compound annual growth rate (CAGR) of 7.2% during the forecast period from 2025 to 2032. The growth trajectory is driven by the increasing awareness among dairy farmers regarding the nutritional requirements…
Croscarmellose Sodium Market to Reach $487 Mn by 2032, Driven by Rising Pharma D …
The global croscarmellose sodium market is projected to witness significant expansion over the forecast period, reflecting the growing adoption of pharmaceutical excipients across diverse applications. Valued at approximately US$ 288.7 million in 2025, the market is expected to reach US$ 487.0 million by 2032, registering a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032. This growth trajectory is driven primarily by increasing demand for orally disintegrating tablets…
Europe Egg Replacement Ingredients Market to Reach $1,711.1 Mn by 2032, Driven b …
The Europe egg replacement ingredients market is witnessing significant expansion, driven by the increasing adoption of plant-based diets and rising consumer awareness regarding health and wellness. The market size is projected to reach US$ 952.2 million in 2025 and is expected to surge to US$ 1,711.1 million by 2032, registering a robust CAGR of 8.7% over the forecast period from 2025 to 2032. The growing demand for clean-label products, vegan…
Kraft Paper Market to Reach US$ 25.0 Billion by 2032: Growth Driven by Rising De …
The global Kraft Paper market is undergoing significant expansion, driven by the accelerating shift toward eco-friendly packaging materials and the rising global awareness surrounding sustainability. As industries worldwide transition from plastic-based packaging to biodegradable alternatives, kraft paper has emerged as one of the most sought-after materials due to its strength, recyclability, and versatility.
According to the latest study by Persistence Market Research, the global Kraft Paper market size is projected to…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
